Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · WELCURE DRUGS & PHARMACEUTICAL · 29 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
WELCURE DRUGS & PHARMACEUTICAL
BSE: 524661
BSE: 524661
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
WELCURE DRUGS & PHARMACEUTICAL
StateQ4 FY26 filed
Last close · 28 Oct 2026₹0.19
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA0.1 · 0.24 · —
WELCURE DRUGS & PHARMACEUTICAL is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 25 | 366 |
| EBITDA (ex other income) | 0 | (0) | (0) | 1 | (7) |
| margin % | 22.5 | — | — | 3.6 | (1.9) |
| Owners' profit | 0 | 0 | (0) | 2 | (5) |
| EPS, as reported (₹) | 0.02 | 0.00 | (0.13) | 0.36 | (0.04) |
| ROE % · ROCE % | 25.4 · 25.4 | 6.7 · 6.7 | (13.1) · (13.1) | 2.1 · 1.2 | (5.7) · (1.9) |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 1.20 | 0.00 |
| Cash from operations | 0 | 0 | (0) | (222) | 2 |
| Capex | 0 | 0 | 0 | (0) | 0 |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · WELCURE DRUGS & PHARMACEUTICAL · 29 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 25 | 9 | 21 | 300 | 66 | 0 | 0 |
| Profit before tax | (0) | 2 | 1 | 3 | 31 | 11 | 1 | (50) |
| Net profit | — | 2 | 0 | 3 | 23 | 9 | 1 | (50) |
| EPS (₹) | 0.26 | 0.16 | 0.04 | 0.33 | 2.07 | 0.76 | 0.13 | (0.40) |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Segment revenue, FY26
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Agriculture | 67 | 18.3 |
| Trading in Agriculture Produce | 300 | 81.7 |
| Total, before eliminations | 367 | 100.0 |
Source: the filed segment block, four quarters summed.
Exhibit 4: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,21,677 | 34.9 | 5.03 | 22.6 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,53,976 | 87.0 | 15.15 | 65.5 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,54,957 | 73.1 | 8.81 | 38.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| LAURUS LABS LIMITED | 1,17,877 | 107.7 | 21.70 | 65.6 | 16.4 | 17.2 | 7.2 | 32.0 |
| ZYDUS LIFESCIENCES LTD | 1,17,315 | 26.2 | 3.97 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| DR. REDDY S LABORATORIES | 1,11,506 | 34.5 | 2.92 | 14.9 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,10,320 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,02,829 | 50.3 | 6.21 | 28.3 | 11.7 | 10.8 | — | 27.3 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 5: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 0.1 | 30.8 | 1 of 158 | 100% |
| P/B | 0.2 | 3.1 | 2 of 163 | 99% |
| ROCE | (1.9) | 10.8 | 158 of 183 | 14% |
| ROE | (5.7) | 9.8 | 151 of 166 | 9% |
| Debt / Equity | 0.0 | 0.2 | 1 of 166 | 79% |
| Revenue growth | (100.0) | 16.3 | 157 of 161 | 0% |
| Profit growth | (2063.6) | 30.9 | 158 of 158 | 0% |
| Market cap | 23 | 806 | 162 of 181 | 11% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · WELCURE DRUGS & PHARMACEUTICAL · 29 October 2026Page 3 of 3
Exhibit 6: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 14 Jul 2026 · Board approves closure of Ahmedabad Corporate Office | board shareholder meetings | medium | — | — |
| 19 Jun 2026 · Company Secretary Palak Jain resigns from Welcure Drugs | management changes | medium | — | — |
| 19 Jun 2026 · Company Secretary Palak Jain resigns from Welcure Drugs | board shareholder meetings | low | — | — |
| 1 Jun 2026 · Newspaper Clipping of Audited Financials Results for the 4th Quarter and Annual year ended 31st March, 2026. | compliance | minimal | — | — |
| 30 May 2026 · Submission of Annual Secretarial Compliance Report for the year ended 31st March. 2026. | compliance | minimal | — | — |
| 29 May 2026 · Audited Standalone Financial Results for the Quarter and Year Ended 31st March, 2026 | results | high | — | — |
| 29 May 2026 · Outcome of the Meeting of Board of Directors of the Company held on today i.e. Friday, 29th May, 2026 | board shareholder meetings | low | — | — |
| 22 May 2026 · Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Audited Financial .... | results | medium | — | — |
| 23 Apr 2026 · <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> .... | compliance | minimal | — | — |
| 3 Apr 2026 · Certificate under Regulation 74(5) of SEBI (Depository and Participants) Regulations, 2018 for the 4th Quarter and Annual year ended 31st MArch, 2026. | compliance | minimal | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in